Gary Unzeitig

Laredo Community College — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index3.4kcitations52works17.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(24), HER2/EGFR in Cancer Research(12), BRCA gene mutations in cancer(12), Estrogen and related hormone effects(9), Cancer Genomics and Diagnostics(8)

Publications50 total

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
UNC Libraries·2024· 1 citedOpen Access
Uptake of Risk-Reducing Surgeries in an International Real-World Cohort of Hispanic Women
JCO Global Oncology·2024Open Access
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination
JAMA Oncology·2024· 17 citedOpen Access
ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy – Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Positive Clinical Stage 2–3 Breast Cancer
Annals of Surgical Oncology·2023
Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer
Annals of Surgical Oncology·2023· 19 citedOpen Access
Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial
Cancer Research·2022
Abstract 2214: Disparity in the uptake of risk-reducing surgery after GCRA in Hispanic patients in Latin America and in the United States
Cancer Research·2022· 1 cited
Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)
Cancer Research·2022· 1 cited
The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial
Cancer Prevention Research·2021· 9 citedOpen Access
Abstract PD2-10: Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)
Cancer Research·2021· 3 cited
Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
Cancer Research·2021· 9 cited
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
UNC Libraries·2020Open Access
Health‐related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients
Cancer·2020· 17 citedOpen Access
A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance)
Cancer·2020· 31 citedOpen Access
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.
Journal of Clinical Oncology·2020· 44 cited
Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles
Annals of Surgical Oncology·2020· 8 cited
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
UNC Libraries·2020Open Access
Cancer Risks Associated With Germline<i>PALB2</i>Pathogenic Variants: An International Study of 524 Families
Journal of Clinical Oncology·2019· 394 citedOpen Access
Pathogenic and likely pathogenic variants in <i>PALB2</i> , <i>CHEK2</i> , and other known breast cancer susceptibility genes among 1054 <i>BRCA</i> ‐negative Hispanics with breast cancer
Cancer·2019· 59 citedOpen Access
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy
JAMA Oncology·2018· 21 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Vera J. Suman(23), Kelly K. Hunt(23), Matthew J. Ellis(22), Jeremy Hoog(14), Mark A. Watson(11), Souzan Sanati(11), A. Marilyn Leitch(11), Jeffrey N. Weitzel(10), John A. Olson(9), Eric P. Winer(9), Lisa A. Carey(9), X. Cynthia(9), Judy C. Boughey(9), Funda Meric‐Bernstam(9), A. Marilyn Leitch(9), Katherine DeSchryver(8), Joseph M. Guenther(8), Erika C. Crouch(8), Olwen Hahn(8), Laura J. Esserman(7)